Trulieve Cannabis is trading at $11.45, down 7.74%, after a DEA judge paused the remaining rescheduling case, delaying a recommendation investors viewed as a near-term catalyst.
- The September 29 stay awaits a decision on adding a Government Accountability Office report and supplemental briefing; it does not reject rescheduling.
- Trulieve traded as low as about $11, roughly 9% lower in extended hours; cannabis ETF MSOS fell about 8%.
- Broader markets were positive, making the policy setback the clearest reported explanation.